Amneal Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Amneal Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Amneal Pharmaceuticals Inc achieved a return on average assets (ROA) of 4.18 % in its third quarter of 2026, this is above AMRX's average return on assets of -2.44%.
Amneal Pharmaceuticals Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $4 billion

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 141 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 1165, from total ROA ranking in the second quarter of 2026 at 1712.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	60.02 %	10.24 %	5.2 %	5.61 %	4.02 %
Y / Y Net Income Change	-	95.49 %	216.84 %	-	54.22 %
Net Income (TTM) in million	175	215	181	128	58
Return On Assets (TTM)	4.18 %	5.89 %	5.08 %	3.63 %	1.66 %
AMRX's Total Ranking	# 1165	# 1712	# 1941	# 1986	# 2214
Total Assets (TTM) in million	5,760	3,773	3,540	3,702	3,600
Seq. Total Assets Change	52.66 %	6.59 %	-4.38 %	2.85 %	5.17 %
Seq. Net Income Change	-	-10.75 %	57.34 %	173.4 %	-49.08 %

AMRX's 5 Years Annual ROA >> Back to AMRX Management Effectiveness >> Compare AMRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 53
Sector	# 142
Overall	# 1042

Return On Assets Statistics
High	Average	Low
5.9 %	-2.44 %	-13.15 %
(Jun 30 2026)		(Dec 31 2019)

Financial Statements
Amneal Pharmaceuticals Inc 's Assets	$ 5,760 million	AMRX's Balance sheet
Amneal Pharmaceuticals Inc 's Income	$ -22 million	Quarterly AMRX's Income Statement
AMRX's Income by Division		See AMRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	5.05 %	0.83 %	-8.6 %	-3.56 %	-16.17 %
Total Assets in million	3,678	3,501	3,473	3,799	3,940
Y / Y Net Income Change	-	-	-	-	-70.59 %
Net Income in million	128	-74	-49	-255	20
Annual Return On Assets	3.48 %	-2.11 %	-1.4 %	-6.71 %	0.51 %

AMRX's 5 Years Annual ROA >> Back to AMRX Management Effectiveness >> Compare AMRX ROA to its Competitors

Comment on AMRX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 3.48 % compared to prior year, due to annual net income growth of % to $127.93 million, while value of Amneal Pharmaceuticals Inc 's overall assets grew just by 5.05 % to $3,678.28 million, compared to $3,678.28 a year before.

More Return On Assets Ratios
AMRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMRX's Competitors
Subscribers only: Roa for Amneal Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for AMRX's Customers

You may also want to know
AMRX's Roi	AMRX's Inventory Turnover Ratio	AMRX's Growth Rates	AMRX's Dividend Comparisons
	AMRX's Profitability Ratios	AMRX's Asset Turnover Ratio	AMRX's Dividend Growth
AMRX's Roe	AMRX's Valuation Ratios	AMRX's Financial Strength Ratios	AMRX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %
Msa Safety Inc	11.01 %
Encompass Health Corporation	10.99 %
Inspire Medical Systems inc	10.89 %
Transmedics Group Inc	10.67 %
Bristol myers Squibb Company	10.47 %
Lemaitre Vascular Inc	10.28 %
Bio rad Laboratories Inc	9.88 %
3m Company	9.60 %
Bioventus Inc	9.47 %
Medinotec Inc	8.67 %
Tactile Systems Technology Inc	8.53 %
Penumbra Inc	8.13 %
Johnson and Johnson	8.06 %
Pacific Health Care Organization Inc	7.83 %
Boston Scientific Corporation	7.82 %
Ani Pharmaceuticals Inc	7.77 %
Stryker Corp	7.66 %
Abbvie Inc	7.48 %
Ensign Group Inc	7.00 %
Pediatrix Medical Group Inc	6.99 %
Quest Diagnostics Inc	6.96 %
Davita Inc	6.65 %
Brightspring Health Services Inc	6.60 %
Ge Healthcare Technologies Inc	5.85 %
Merit Medical Systems Inc	5.72 %
Incyte Corporation	5.48 %
Labcorp Holdings Inc	5.36 %
Sotera Health Company	5.26 %

Date modified: 2026-11-10T05:28:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.